Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

The Emirates Drug Establishment announced on Monday it had authorised the use of Inpefa (sotagliflozin), a treatment shown in ...

ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

The Tennessee Volunteers and the rest of the nation made huge moves when it comes to signing day, and the Tennessee Volunteers have officially missed on their first current commit, as they have lost ...

Tennessee football is still waiting for four-star athlete Salesi Moa to sign as the first day of the early signing period winds down. Utah and Michigan made a late push to poach the coveted prospect, ...

BLOOMINGTON, Minn. — When folks want to shop till they drop, Mall of America remains the center of the universe for consumers. MOA announced that the mall set a new record for its busiest Black Friday ...

HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...

Patients prescribed SGLT2 inhibitors less likely to exhibit nodule growth and to undergo a surgical intervention. HealthDay News — For patients with diabetes and early-stage pulmonary malignancies, ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...